Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 2, 2010, Pages 71-75

  Hamada, Toshihiro ^a   Mizuta, Einosuke ^a   Kondo, Takehito ^a   Hirai, Masayuki ^a   Yamada, Kensaku ^a   Kato, Masahiko ^a   Shigemasa, Chiaki ^a   Yamamoto, Yasutaka ^b   Ninomiya, Haruaki ^a   Igawa, Osamu ^a   Hisatome, Ichiro ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blockers; Antihypertensive diuretics; CAS 124750 99 8; CAS 58 93 5; Hydrochlorothiazide; Losartan; Serum urate levels

Indexed keywords

CANDESARTAN; ELECTROLYTE; GLUCOSE; HYDROCHLOROTHIAZIDE; LOSARTAN; TELMISARTAN; URATE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SCREENING; ELECTROLYTE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; LOW DRUG DOSE; MALE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINALYSIS;

EID: 77249179293     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296251     Document Type: Article

References (18)

1. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000;18:1149-54.
2. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144-50.
3. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
4. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ. 2003;326: 1427-34.
5. Reaven GM. The kidney: an unwilling accomplice in syndrome X. AmJ Kidney Dis. 1997;30:928-31.
6. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007;320:211-7.
7. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447-52.
8. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT1) in Hypertensive Patients AmJ Hypertens. 2008;21:1157-62.
9. Saruta T, Ogihara T, Matsuoka H, Suzuki H, Toki M, Hirayama Y, et al. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res. 2007;30:729-39.
10. Shimosawa T, Gohchi K, Yatomi Y, Fujita T. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/ hydrochlorothiazide vs. candesartan/ amlodipine. Hypertens Res. 2007;30:831-7.
11. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004;1:10.
12. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, et al. Plasma urate level is directly regulated by a voltagedriven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem. 2008;283:26834-8.
13. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-6.
14. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355-60.
15. Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol. 2005;96: 1576-8.
16. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269-75.
17. Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serumuric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041-9.
18. Naritomi H, Fujita T, Ito S, Ogihara T, Shimada K, Shimamoto K, et al. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) Study. Hypertens Res. 2008;31:295-304.